<DOC>
	<DOCNO>NCT02940730</DOCNO>
	<brief_summary>This study evaluate pharmacokinetic property dalbavancin administer intravenous infusion instill peritoneal space patient undergoing peritoneal dialysis . The patient receive intravenous dalbavancin follow intensive plasma peritoneal dialyse fluid sample . Following washout phase , patient receive dalbavancin instill peritoneal space follow intensive plasma peritoneal dialyse fluid sampling .</brief_summary>
	<brief_title>Evaluation Intravenous Intraperitoneal Pharmacokinetics Dalbavancin Peritoneal Dialysis Patients</brief_title>
	<detailed_description>This study open label , cross-over study , evaluate plasma peritoneal fluid pharmacokinetics ( PK ) dalbavancin either intravenous intraperitoneal administration . In first part study , ten patient administer dalbavancin study day 0 . Pharmacokinetic analysis conduct day 0 , 7 , 14 . In second part study , 10 patient cross-over administered dalbavancin study day 0 . Pharmacokinetic analysis conduct day 0 , 7 , 14 . Sample Size : Ten ( n=10 ) patient evaluate pharmacokinetic evaluation . Since descriptive pharmacokinetic study sample size calculation perform Plasma peritoneal fluid sampling : Dalbavancin administer study day 0 . On intravenous administration day dalbavancin administer 30-minute intravenous ( IV ) infusion . On intraperitoneal administration day , dalbavancin administer peritoneal dialysis fluid 6 hour dwell time . On day 0 , patient undergo plasma peritoneal fluid pharmacokinetic sample determination dalbavancin concentration time zero , 1 hour , 2 hour , 3 hour , 4 hour , 6 hour , time volume exchange . Patients give specimen collection cup ask collect ~30 ml peritoneal dialysate follow schedule nocturnal dwell approximately 24 hour follow administration dalbavancin administration . Patients report single PK measurement study day 7 14 . ( 18 total plasma 18 total peritoneal fluid sample per patient ) . Blood sample draw peripherally insert intravenous catheter . Peritoneal fluid sample draw already place peritoneal dialysis catheter . Blood sample immediately centrifuge 3000g plasma peritoneal fluid sample store -80°C analysis . Description , Risks Justification Procedures Data Collection Tools : Visit 1 4 : ( ~8 hour ) : On visit 1 4 patient undergo intensive PK sampling . Subjects admit Clinical Translational Research Center ( CTRC ) morning `` saline-lock '' place . A pre-dose sample safety lab ( comprehensive metabolic panel urine pregnancy test woman childbearing potential ) obtain . The dalbavancin 1500 mg either administer intravenously ( Visit 1 ) intraperitoneal space ( Visit 4 ) use patient 's exist peritoneal dialysis catheter patient currently prescribe dialysate . Following blood peritoneal fluid collection second dialysis volume exchange , subject discharge asked return schedule time day 7 . Patients also give specimen collection instruction collect approximately 30 ml peritoneal dialysate follow even nocturnal dwell . The collected dialysate return investigator . Visit 2 , 3 , 5 , 6 : ( ~60 minute ) : A `` saline-lock '' place blood peritoneal fluid sample collect visit . All blood peritoneal fluid draw complete CTRC . The patient discharge follow visit schedule day 14 next intensive PK sample visit . Washout : During washout portion study patient ask come visit . This time-frame ensure medication ( dalbavancin ) leave patient ' system administer another dose medication . Laboratory test : The laboratory test perform part study include pregnancy test confirm eligibility comprehensive metabolic panel determine eligibility evaluate safety . Pharmacokinetic Assessments : 4 mL blood collect purple top ( Ethylenediaminetetraacetic acid ) tube 4 mL peritoneal fluid urine collection cup pre-dose , 1 , 2 , 3 , 4 , 6 , dialysis volume exchange 1 , 8 , dialysis volume exchange 2 post dose quantification dalbavancin . Blood peritoneal fluid place ice bath chill centrifuge . Plasma harvest within 30 minute blood sample store -80ºC assaying .</detailed_description>
	<mesh_term>Peritonitis</mesh_term>
	<mesh_term>Dalbavancin</mesh_term>
	<mesh_term>Teicoplanin</mesh_term>
	<criteria>Age ≥18 ≤89 year age Actively receive chronic peritoneal dialysis Ability willingness provide write informed consent Patients currently receive antimicrobial therapy receive antibiotic therapy within 14 day prior study Patients know hypersensitivity reaction dalbavancin glycopeptides Prisoners Pregnant breastfeed woman Decisionally challenge patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>